<p>Quality by Design (QbD) has emerged as a systematic and proactive approach in pharmaceutical development, ensuring consistent product quality through a thorough understanding of formulation components and critical process parameters. In the context of phytosomal formulations, which increase bioavailability and therapeutic effectiveness of phytoconstituents. QbD-driven risk analysis is essential for optimizing formulation parameters and reducing variability. The incorporation of risk assessment tools, such as Fault Tree Analysis (FTA), Ishikawa fishbone diagrams, Failure Mode and Effect Analysis (FMEA), and Design of Experiments (DoE), facilitates the identification and management of critical material attributes (CMAs) and critical process parameters (CPPs) that profoundly affect the quality attributes of phytosomal carriers. Utilizing a scientific and data-driven methodology, QbD enhances formulation development, resulting in superior stability, encapsulation efficiency, and controlled release properties. Furthermore, the utilization of QbD principles ensures regulatory adherence, improves repeatability, and minimizes batch-to-batch variability, resulting in a more dependable and scalable production process. The pharmaceutical industry is shifting to a methodical and knowledge-based approach, and QbD-driven risk analysis in phytosomal formulations is a transformational tool for maximizing the therapeutic potential of bioactive phytoconstituents.</p> Graphical Abstract <p></p>